Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hepatic adeno-associated virus (AAV)-serotype 2 mediated gene transfer results in transgene product expression that is sustained in experimental animals but not in human subjects. We hypothesize that this is caused by rejection of transduced hepatocytes by AAV capsid-specific memory CD8(+) T cells reactivated by AAV vectors. Here we show that healthy subjects carry AAV capsid-specific CD8(+) T cells and that AAV-mediated gene transfer results in their expansion. No such expansion occurs in mice after AAV-mediated gene transfer. In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Detection of AAV components by the innate immune system also leads to the AAV-directed adaptive immune response and potential loss of transgene expression in transduced cells (Mingozzi et al., 2007; Xiang et al., 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Mingozzi et al., 2007
In the citing paper
“Early successes in this field were initially dampened by reports of patients who developed vector insertion-related leukemias directly linked to the viral platform used for transgene delivery11–18.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [12]
In the citing paper
“Evidence from early clinical trials, along with subsequent laboratory studies, suggest that CD8+ T cell responses against AAV capsid target transduced hepatocytes (16–18).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [17]
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [5]
In the citing paper
“Although AAV infection is non-pathogenic in humans, initial exposure induces humoral and cellular anti-capsid response that are reactive to rAAV due to capsid similarity (4, 5).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationMemory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M. A., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., et al. (2002) · Nature Medicine · doi:10.1038/nm0402-379 · Cited by 1,571
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Wang, L., Nichols, T. C., Read, M. S., Bellinger, D. A., & Verma, I. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0031 · Cited by 176
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J., & High, K. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.009 · Cited by 96
Self-citation
Research works printed but not linked: 1
- Muzyczka, N. & Berns, K.I. Parvoviridae: The Viruses and Their Replication, 2327–2359 (Lippincott Williams & Wilkins, Philadelphia, 2001).
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationDunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“Subsequent studies revealed that expression of the factor IX transgene in humans was of short duration because of an immune response to the AAV capsid (42).”
Self-citationLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
Advances in therapeutic applications of extracellular vesicles
Wiklander, O. P. B., Brennan, M. Á., Lötvall, J., Breakefield, X. O., & EL Andaloussi, S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8521 · Cited by 1,039
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
“Indeed, AAV2 capsid-primed CD8 þ memory T cells in humans cross-react with epitopes from AAV8 and AAV1 capsid and result in expansion of functional CD8 þ cytotoxic lymphocytes that are indistinguishable from those elicited by AAV2 capsid epitopes (Mingozzi et al. , 2007a).”
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“activation leads to clearance of AAV-transduced cells.(67) Human studies show expansion of capsid T cells”
Self-citationGene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Self-citationEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“These observations were associated with the expansion of capsid-specific CD8 T cells, which likely were responsible for the immune rejection of the transduced hepatocytes.(58)”
BackgroundSelf-citationAntigen-presenting cell function in the tolerogenic liver environment
Thomson, A. W., & Knolle, P. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2858 · Cited by 805
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“CD8 T Cell Responses to Capsid In the first liver-directed gene therapy trial with AAV vectors (performed with an AAV2 vector in patients with hemophilia B), a loss of factor IX transgene expression and transient mild elevations of liver enzymes in circulation were correlated with a CD8 T cell response against the vir…”
BackgroundHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Self-citationEngineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Part of this variability may be explained, in part, by a hypothesized cellular immune response to capsid peptides presented by transduced hepatocytes that can result in reduced or loss of transgene expression, thereby limiting efficacy.(214) Additionally, vector CpG motifs may potentially be immune stimulatory and”
BackgroundDystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655
Progress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“In addition, a higher prevalence of T cell responses in PBMCs or splenocytes is observed after several rounds of in vitro expansion, suggesting that the frequency ofAAV-specific T cells is too low to be efficiently detected ex vivo.(40,45) The fact that flow cytometry-based assessment of differentiation markers eviden…”
BackgroundResultInfluentialSelf-citationZhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
“It was concluded that this CD8 T cell response to input capsid eliminated AAV2-transduced hepatocytes (43).”
BackgroundHigh, K. A., & Roncarolo, M. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1706910 · Cited by 555
Self-citationEntering the Modern Era of Gene Therapy
Anguela, X. M., & High, K. A. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043332 · Cited by 471
“Both events were eventually attributed to the destruction of transduced hepatocytes by AAV capsid-specific memory CD8+ T cells (59).”
BackgroundSelf-citationImmunogenicity and toxicity of AAV gene therapy
Ertl, H. C. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975803 · Cited by 402
“T cells were further characterized as belonging to the CD8 T cell subset and it was thought that their reflected a recalled memory response of T cells that had been induced by a previous natural infection (7).”
BackgroundSelf-citationTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
“12,194,198,210 The most common course of treatment has been corticosteroid administration, 12,196,210 which has not always been successful to control anti-AAV immune responses and has known side effects.”
BackgroundLamers, C. H. J., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., & Gratama, J. W. (2011) · Blood · doi:10.1182/blood-2010-07-294520 · Cited by 368
Gene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
Berntorp, E., Fischer, K., Hart, D. P., Mancuso, M. E., Stephensen, D., Shapiro, A. D., & Blanchette, V. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00278-x · Cited by 328
Recent Advances in Lentiviral Vector Development and Applications
Mátrai, J., Chuah, M. K., & VandenDriessche, T. (2010) · Molecular Therapy · doi:10.1038/mt.2009.319 · Cited by 347
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“Indeed, efficient AAV-specific T cells detection in peripheral blood and spleen requires several rounds of in vitro expansion with peptide libraries derived from the capsid VP1 (50, 56).”
BackgroundInfluentialSelf-citationOvercoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
“Thus, although increasing the total capsid dose (empty particles and DNA-bearing vector particles) helps to evade anti-AAV humoral responses, it may increase the likelihood of triggering potentially harmful T cell responses against the AAV capsid (1, 2, 11).”
BackgroundSelf-citationKeeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
“The introduction of the sequential mutations between these putative evolutionary intermediates highlights in Figure 5C the overlap between the mutations and 2/4 human T-cell epitopes (Mingozzi et al., 2007), and 2/2 mouse B-cell epitopes (Gurda et al., 2012).”
BackgroundInfluentialMingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Self-citationNiemeyer, G. P., Herzog, R. W., Mount, J., Arruda, V. R., Tillson, D. M., Hathcock, J., van Ginkel, F. W., High, K. A., & Lothrop, C. D. (2009) · Blood · doi:10.1182/blood-2008-10-181479 · Cited by 276
Self-citationAyuso, E., Mingozzi, F., Montane, J., Leon, X., Anguela, X. M., Haurigot, V, Edmonson, S. A., Africa, L., Zhou, S., High, K. A., et al. (2010) · Gene Therapy · doi:10.1038/gt.2009.157 · Cited by 272
Self-citationMeliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Self-citationMingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254
Self-citationMultiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A
George, L. A., Monahan, P. E., Eyster, M. E., Sullivan, S. K., Ragni, M. V., Croteau, S. E., Rasko, J. E. J., Recht, M., Samelson-Jones, B. J., MacDougall, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104205 · Cited by 243
Self-citationClinical development of gene therapy: results and lessons from recent successes
Kumar, S. R., Markusic, D. M., Biswas, M., High, K. A., & Herzog, R. W. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.34 · Cited by 232
Self-citationCraik, C. S., Page, M. J., & Madison, E. L. (2011) · Biochemical Journal · doi:10.1042/bj20100965 · Cited by 237
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238
Self-citationUnraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
“A similar series of events was observed in the next patient enrolled in the mid-dose cohort (Subject G; 4 · 10(11) vg/kg), from whom PBMCs were collected in order to perform a posteriori immune analyses.(41) IFN-c enzyme-linked immunospot (ELISpot) assays showed a response to AAV2 capsid but not FIX, and allowed the i…”
BackgroundMethodInfluentialSelf-citationAAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9
Li, A., Tanner, M. R., Lee, C. M., Hurley, A. E., De Giorgi, M., Jarrett, K. E., Davis, T. H., Doerfler, A. M., Bao, G., Beeton, C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.017 · Cited by 230
“This is an intriguing possibility given other recent data and the known lag in CD8 T cell response to AAV capsid in humans receiving liver-directed gene therapies.(21)”
Integration-deficient Lentiviral Vectors: A Slow Coming of Age
Wanisch, K., & Yáñez-Muñoz, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.122 · Cited by 222
Wright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219
“A cluster of differentiation (CD) 8 T-cell response directed against AAV capsid was implicated in the recognition and clearance of transduced hepatocytes in clinical trials using AAV2-hFIX [35,36] and AAV8-hFIX [11], and peptides derived from empty capsids themselves have been demonstrated to gain access to MHC Class…”
In utero CRISPR-mediated therapeutic editing of metabolic genes
Rossidis, A. C., Stratigis, J. D., Chadwick, A. C., Hartman, H. A., Ahn, N. J., Li, H., Singh, K., Coons, B. E., Li, L., Lv, W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0184-6 · Cited by 216
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66778 · Cited by 215
“…systemically may be neutralized by anti-AAV antibodies (42–44), which are highly prevalent in humans (41); finally, systemic exposure to high doses of AAV vectors may trigger the activation of CD8 + T cell responses directed against the viral capsid in a dose-dependent manner (16, 42, 50, 51).”
Self-citationGeorge, L. A., Ragni, M. V., Rasko, J. E. J., Raffini, L. J., Samelson-Jones, B. J., Ozelo, M., Hazbon, M., Runowski, A. R., Wellman, J. A., Wachtel, K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.001 · Cited by 213
“As previously reported, expression from the vector was subtherapeutic or limited in duration due to a cellular immune response to the AAV capsid, which prevented analysis of expression durability and long-term efficacy.(5,20) However, this cohort provides the longest longitudinal safety data after systemic AAV adminis…”
BackgroundSelf-citationWang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212
“Much is being learned about host–vector interactions, such as the role of innate immunity and the activation of T cells and B cells in response to the vector and its transgene product (Manno et al. , 2006; Cao et al. , 2007; Mingozzi et al. , 2007; Zhu et al. , 2009).”
Stroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.175620 · Cited by 209
Self-citationGene Delivery to the Juvenile Mouse Liver Using AAV2/8 Vectors
Cunningham, S. C., Dane, A. P., Spinoulas, A., & Alexander, I. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.72 · Cited by 206
Successes and challenges in clinical gene therapy
Kohn, D. B., Chen, Y. Y., & Spencer, M. J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00390-5 · Cited by 184
“These SAEs were attributed to CD8 T cell mediated attack against hepatocytes presenting capsid on MHC [106, 109].”
BackgroundMonteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206
Mingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Self-citationEvolution of a designed protein assembly encapsulating its own RNA genome
Butterfield, G. L., Lajoie, M. J., Gustafson, H. H., Sellers, D. L., Nattermann, U., Ellis, D., Bale, J. B., Ke, S., Lenz, G. H., Yehdego, A., et al. (2017) · Nature · doi:10.1038/nature25157 · Cited by 199
Manufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205
Multifunctional CRISPR-Cas9 with Engineered Immunosilenced Human T Cell Epitopes
Ferdosi, S. R., Ewaisha, R., Moghadam, F., Krishna, S., Park, J. G., Ebrahimkhani, M. R., Kiani, S., & Anderson, K. S. (2019) · Nature Communications · doi:10.1038/s41467-019-09693-x · Cited by 204
Recent developments in adeno‐associated virus vector technology
Büning, H., Perabo, L., Coutelle, O., Quadt‐Humme, S., & Hallek, M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1205 · Cited by 187
“[163] showed that the human population indeed harbours capsid specific memory T cells and that these memory CD8+ T cells react in vitro with capsid epitopes of AAV-2 and other serotypes such as AAV-8.”
BackgroundAdeno-associated virus 2 infection in children with non-A–E hepatitis
Ho, A., Orton, R., Tayler, R., Asamaphan, P., Herder, V., Davis, C., Tong, L., Smollett, K., Manali, M., Allan, J., et al. (2023) · Nature · doi:10.1038/s41586-023-05948-2 · Cited by 174
“In support of this notion, a CD8 + cell-mediated response directed against the AAV2 viral capsid (VP1) in association with hepatitis was reported in early trials of AAV2 when used as a vector for gene therapy 17–19 .”
Byrne, L. C., Dalkara, D., Luna, G., Fisher, S. K., Clérin, E., Sahel, J.-A., Léveillard, T., & Flannery, J. G. (2015) · Journal of Clinical Investigation · doi:10.1172/jci65654 · Cited by 182
Gene-based therapies for neurodegenerative diseases
Sun, J., & Roy, S. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00778-1 · Cited by 187
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192
“In addition, AAV2 capsid–specific CD8+ T cells were detectable following vector administration, and their frequency expanded and contracted in temporal correlation with hepatocellular injury (2).”
BackgroundMethodInfluentialSelf-citationKonkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., et al. (2021) · Blood · doi:10.1182/blood.2019004625 · Cited by 189
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180
Kruzik, A., Fetahagic, D., Hartlieb, B., Dorn, S., Koppensteiner, H., Horling, F. M., Scheiflinger, F., Reipert, B. M., & de la Rosa, M. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.014 · Cited by 182
“Therefore, it could be speculated that anti-AAV T cells are tissue resident(25) or circulating at very low frequencies.(21) In addition to IFN-g, the major cytokine in antiviral immune response,(26) IL-2 responses, a marker for activation of naive cells and central memory cells,(27) were also investigated.”
BackgroundDNA Shuffling of Adeno-associated Virus Yields Functionally Diverse Viral Progeny
Koerber, J. T., Jang, J.-H., & Schaffer, D. V. (2008) · Molecular Therapy · doi:10.1038/mt.2008.167 · Cited by 181
Innate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178
“…showed elevated circulating F.IX at 2 weeks, followed by a decline of transgene with a concomitant rise in liver enzymes, indicative of the destruction of hepatocytes; this damage was most likely mediated by a CD8+ T cell response against the AAV capsid (Manno et al., 2006; Mingozzi et al., 2007).”
BackgroundComplement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors
Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. M., Bartlett, J. S., & Muruve, D. A. (2008) · Journal of Virology · doi:10.1128/jvi.01990-07 · Cited by 177
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Mueller, C., Chulay, J. D., Trapnell, B. C., Humphries, M., Carey, B., Sandhaus, R. A., McElvaney, N. G., Messina, L., Tang, Q., Rouhani, F. N., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70314 · Cited by 169
“However, the significance of anti-capsid effector T cell responses is unclear, and at least some studies have suggested that they target transduced cells and limit the duration of transgene expression (9, 10).”
BackgroundKwon, I., & Schaffer, D. V. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9431-0 · Cited by 164
Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2013.9 · Cited by 165
The emerging role of miRNAs in inflammatory bowel disease: a review
Chapman, C. G., & Pekow, J. R. (2014) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x14547360 · Cited by 172
Martino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
Self-citationPaulk, N. K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A. P., Haft, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.021 · Cited by 161
Self-citationDurability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 172
“durability Early clinical trials of rAAV-mediated gene therapy highlighted the impact of the adaptive immune response on successful gene transfer.(11,100,101) The adaptive immune response is considered the second line of defense, with the ability to elicit an antigen-specific response that targets and eliminates patho…”
BackgroundTailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155
CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
Arjomandnejad, M., Kopec, A. L., & Keeler, A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020287 · Cited by 171
Ju, W., Perkins, G. A., Kim, K.-Y., Bastola, T., Choi, W.-Y., & Choi, S. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101136 · Cited by 167
Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria
D’Avola, D., López‐Franco, E., Sangro, B., Pañeda, A., Grosios, N., Gil-Fariña, I., Benito, A., Twisk, J., Paz, M., Ruiz, J. A., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.012 · Cited by 144
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Lykken, E. A., Shyng, C., Edwards, R. J., Rozenberg, A. J., & Gray, S. J. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-018-9234-0 · Cited by 154
“Further, these preexisting memory cells are less frequent in the blood than spleen [101] and require multiple rounds of stimulation to observe [100, 101].”
BackgroundCurrent clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 161
“22 Currently, most AAV vectors are delivered by intravenous infusion, including five of the seven FDA-approved AAV vectors.”
B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Corti, M., Elder, M., Falk, D., Lawson, L., Smith, B., Nayak, S., Conlon, T., Clément, N., Erger, K., Lavassani, E., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.33 · Cited by 140
Amado, D., Mingozzi, F., Hui, D., Bennicelli, J. L., Wei, Z., Chen, Y., Bote, E., Grant, R. L., Golden, J. A., Narfstrom, K., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000659 · Cited by 140
Self-citationAdeno-Associated Virus Gene Therapy for Hemophilia
Samelson‐Jones, B. J., & George, L. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033013 · Cited by 150
Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis
Le Meur, G., Lebranchu, P., Billaud, F., Adjali, O., Schmitt, S., Bézieau, S., Péréon, Y., Valabregue, R., Ivan, C., Darmon, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.014 · Cited by 137
Microdystrophin Ameliorates Muscular Dystrophy in the Canine Model of Duchenne Muscular Dystrophy
Shin, J., Pan, X., Hakim, C. H., Yang, H. T., Yue, Y., Zhang, K., Terjung, R. L., & Duan, D. (2013) · Molecular Therapy · doi:10.1038/mt.2012.283 · Cited by 146
Intra, J., & Salem, A. K. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.014 · Cited by 137
“Promising results with some viral vectors such as AAV have progressed into human clinical trials, but the long-term safety concerns of viral vectors still exist and therapeutic levels of expression remain transient in the clinic [9, 10 ].”
BackgroundSystematic Evaluation of AAV Vectors for Liver directed Gene Transfer in Murine Models
Wang, L., Wang, H., Bell, P. L., McCarter, R., He, J., Calcedo, R., Vandenberghe, L. H., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.246 · Cited by 142
Alipogene Tiparvovec: A Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency
Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-014-0339-9 · Cited by 144
Markusic, D. M., Herzog, R. W., Aslanidi, G. V., Hoffman, B. E., Li, B., Li, M., Jayandharan, G. R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.172 · Cited by 131
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Transient transfection methods for clinical adeno-associated viral vector production
Wright, J. F. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.064 · Cited by 131
The Complex and Evolving Story of T cell Activation to AAV Vector-encoded Transgene Products
Mays, L. E., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.250 · Cited by 144
The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques
Wang, L., Calcedo, R., Wang, H., Bell, P., Grant, R., Vandenberghe, L. H., Sanmiguel, J., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.245 · Cited by 130
Meliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127
“Second, the ability to lower the vector dose to achieve full therapeutic efficacy would confer a clear advantage in terms of avoidance of CD8(1) T-cell responses directed to the capsid.(11) This point can be extrapolated from a number of preclinical and clinical studies,(12,37-40) suggesting that at low vector doses i…”
BackgroundSelf-citationAdeno-associated Virus Vectors in Gene Therapy
Mary, B., Khan, N., Arumugam, S., Saxena, H., Kumar, M., Manimaran, P., Chattopadhyay, S., & Jayandharan, G. R. (2018) · Springer eBooks · doi:10.1007/978-981-13-0481-1_2 · Cited by 127
Metadata
- Authors
- Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., Pierce, G. F., Ertl, H. C. J., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- The University of Sydney (AU)
- Hemophilia Center of Western Pennsylvania (US)
- The Wistar Institute (US)
- Corresponding author
- High, Katherine A
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-03-18
- Volume
- 13
- Issue
- 4
- Pages
- 419-422
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2007261697
- Cited by
- 748
- References
- 8
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 43 · 2023: 41 · 2022: 34 · 2021: 58 · 2020: 43 · 2019: 40 · 2018: 28 · 2017: 38 · 2016: 24 · 2015: 40 · 2014: 41 · 2013: 37 · 2012: 40
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1f32hl069647-01)
- National Heart, Lung, and Blood Institute (F32 HL69647, P01HL078810, T32HL007439)
- National Institute of Allergy and Infectious Diseases (P30AI045008)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- National Center for Research Resources (M01RR000056, M01RR000240)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus, AAV capsid, CD8+ T cells, AAV serotype 2, gene transfer, T cell memory, T cell proliferation
- MeSH terms
- Dependovirus, Animals, Capsid, Humans, Lymphocyte Activation, Parvoviridae Infections, Peptides, Gene Transfer Techniques, CD8-Positive T-Lymphocytes, Hepatocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.